title: [Possible applications of rac-hopantenic acid in the treatment of anxiety and depressive disorders in patients with chronic cerebral ischemia].
abstract: OBJECTIVE
  To evaluate the efficacy and tolerability of rac-hopantenic acid (pantogam activ) in patients with mixed anxiety-depressive disorder and anxiety-depressive disorder with chronic cerebral ischemia.
  
  
  METHODS
  A total of 50 patients were examined (30 patients in the main group, 20 patients in the control one). All patients received standard therapy with SSRI antidepressants. Rac-hopantenic acid at a daily dose of 1200 mg was included in the complex therapy of patients of the main group. Duration of the therapy with rac-hopantenic acid was 21 days. Psychopathological, psychometric and detailed somatic examinations were performed.
  
  
  RESULTS
  In the main group, the combination of pantogam activ and antidepressants promoted distinct balanced nootropic, antidepressant and anxiolytic effects, as well as the improvement of health outcomes. The reduced total number of adverse events (less frequent drowsiness and headaches) was noted as well.
  
  
  CONCLUSIONS
  The rapid and reliable reduction of anxiety, depression and cognitive impairment during concomitant therapy with antidepressants and pantogam activ was identified.
authors.affiliation: Scientific and Practical Neuropsychiatric Center, Moscow Health Department, Moscow, Russia.
authors.forename: A B
authors.initials: AB
authors.lastname: Gekht
authors.affiliation: Serbsky Federal Medical Research Center for Psychiatry and Narcology, Moscow, Russia.
authors.forename: L S
authors.initials: LS
authors.lastname: Kanaeva
authors.affiliation: Serbsky Federal Medical Research Center for Psychiatry and Narcology, Moscow, Russia; Scientific and Practical Neuropsychiatric Center, Moscow Health Department, Moscow, Russia.
authors.forename: A S
authors.initials: AS
authors.lastname: Avedisova
authors.affiliation: Serbsky Federal Medical Research Center for Psychiatry and Narcology, Moscow, Russia; Scientific and Practical Neuropsychiatric Center, Moscow Health Department, Moscow, Russia.
authors.forename: M P
authors.initials: MP
authors.lastname: Marachev
authors.affiliation: Serbsky Federal Medical Research Center for Psychiatry and Narcology, Moscow, Russia; Scientific and Practical Neuropsychiatric Center, Moscow Health Department, Moscow, Russia.
authors.forename: K V
authors.initials: KV
authors.lastname: Zakharova
authors.affiliation: Scientific and Practical Neuropsychiatric Center, Moscow Health Department, Moscow, Russia.
authors.forename: G K
authors.initials: GK
authors.lastname: Dashkina
authors.affiliation: Scientific and Practical Neuropsychiatric Center, Moscow Health Department, Moscow, Russia.
authors.forename: E V
authors.initials: EV
authors.lastname: Kulikova
mesh_terms: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000150:complications / Q000188:drug therapy*; D002545:Brain Ischemia / Q000150:complications*; D003866:Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D018697:Nootropic Agents; D010205:Pantothenic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011594:Psychometrics; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D018697:Nootropic Agents; C016030:pantogab; D010205:Pantothenic Acid; D005680:gamma-Aminobutyric Acid